H-SLFVLGLFL-OH

Ref. 3D-PP47067

Información del producto

• Nombre: H-SLFVLGLFL-OH
• Sinónimos: NH2-Ser-Leu-Phe-Val-Leu-Gly-Leu-Phe-Leu-OH

Descripción

Peptide H-SLFVLGLFL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SLFVLGLFL-OH include the following: Profile of elotuzumab and its potential in the treatment of multiple myeloma YC Liu, S Szmania, F van Rhee - Blood and lymphatic cancer , 2014 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.2147/BLCTT.S49780 Immunotherapy for the treatment of multiple myeloma SH Jung , HJ Lee, MC Vo , HJ Kim, JJ Lee - Critical reviews in oncology , 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1040842816302529 A novel immunogenic CS 1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma J Bae, W Song, R Smith, J Daley, YT Tai - British journal of , 2012 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.2012.09111.x Dendritic cells and peptide-based vaccine in multiple myeloma J Bae, RH Prabhala , NC Munshi - Advances in Biology and Therapy of , 2012 - Springerhttps://link.springer.com/chapter/10.1007/978-1-4614-5260-7_6 Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders J Bae, R Smith, J Daley, N Mimura, YT Tai - Clinical Cancer , 2012 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/18/17/4850/283647 A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients J Bae, R Prabhala , A Voskertchian, A Brown - Leukemia, 2015 - nature.comhttps://www.nature.com/articles/leu2014159 Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma J Bae, F Accardi, T Hideshima, YT Tai, R Prabhala - Leukemia, 2022 - nature.comhttps://www.nature.com/articles/s41375-021-01301-6 Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma J Bae, D Keskin , YT Tai, T Hideshima, N Munshi - Blood, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119823832 Vaccination of multiple myeloma: Current strategies and future prospects A Allegra , G Penna, V Innao , B Greve - Critical Reviews in , 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1040842815001213

• Marca: Biosynth